ONC vs VRTX
BeOne Medicines AG and Vertex Pharmaceuticals, both Healthcare
Vertex Pharmaceuticals is the larger company at $129B against $40B. Over the past year VRTX returned +32% against +3.8% for ONC.
| Figure | ONC | VRTX |
|---|---|---|
| Last close | $351 | $507 |
| Market cap | $40B | $129B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 29.5 |
| 1-year return | +3.8% | +32% |
| 5-year return | -6.6% | +169% |
| RyuScoresector-relative, 1–10 | n/a | 57/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
BeOne Medicines AG
Vertex Pharmaceuticals
Revenue of $3.3B in Q2 2026, net income $1.1B. Its largest reported line is TRIKAFTAKAFTRIO, 75% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.